Aggressive Lymphomas
News
ICER assesses value of CAR T-cell therapies
The Institute for Clinical and Economic Review (ICER) has made policy recommendations intended to ensure affordability and access to chimeric...
News
Health Canada approves SC rituximab for CLL
Health Canada has approved a subcutaneous (SC) formulation of rituximab (Rituxan®) to treat patients with chronic lymphocytic leukemia (CLL). The...
From the Journals
Experimental voxtalisib shows mixed results in phase 2 study
The novel pan-P13K/mTOR inhibitor induced complete responses in some patients with follicular lymphoma, but not aggressive malignancies, including...
News
FDA approves BV plus chemo for untreated cHL
The US Food and Drug Administration (FDA) has approved brentuximab vedotin (ADCETRIS) in combination with chemotherapy for adults with previously...
News
Metabolic changes in T cells may limit CAR potential in kids
Researchers analyzed peripheral blood T cells from 157 pediatric cancer patients at diagnosis and after chemotherapy and found the potential to...
From the Journals
Time to rethink MCL treatment, trial design
Dr. Leonid Yavorkovsky of Kaiser Permanente San Jose Medical Center questions the traditional approach to treatment of class mantle cell lymphoma...
Conference Coverage
CAR T before transplant yields durable remission in B-cell malignancies
SALT LAKE CITY – The analysis also showed the value of next-generation sequencing in detecting relapse earlier than flow cytometry can.
News
Lymphoma, breast cancer survivors have greater risk of CHF
ORLANDO—Results of a retrospective study showed that survivors of lymphoma or breast cancer had a significantly greater risk of congestive heart...
Conference Coverage
Outpatient CAR T infusions feasible using liso-cel
SALT LAKE CITY – Though most patients are admitted later, hospital stays are shorter with outpatient CAR T infusion.
Conference Coverage
Best options for treating relapsed/refractory PTCL
LA JOLLA, CALIF. – Hematologists from the Royal Marsden Hospital in London review their best practices for the hardest to treat PTCL cases.
From the Journals
Immunotherapy regimen influences inflammatory arthritis presentation
Variations in the clinical presentation of immunotherapy-induced inflammatory arthritis is partly explained by which treatment regimen is used to...